YK-1101

N/A

Report date: 2025/08/28 20:00:09

Base Information

Drug NameYK-1101
Drug Alias Nameautologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T) therapy ( Yingkai Saiwei)YK1101YK-1101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionAnti-Melanoma-associated antigen 4
TargetsMelanoma-associated antigen 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPeking University
China Registration ClassN/A

Develop Information

Active CompaniesYingkai Saiwei (Beijing) Biotechnology Co LtdPeking University
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A